Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer

Bergquist, 2002, Hepatic and extrahepatic malignancies in primary sclerosing cholangitis, J Hepatol, 36, 321, 10.1016/S0168-8278(01)00288-4

Chalasani, 2000, Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study, Hepatology, 31, 7, 10.1002/hep.510310103

Fisher, 1995, CA 19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation, Liver Transpl Surg, 1, 94, 10.1002/lt.500010204

Patel, 2000, The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis, Am J Gastroenterol, 95, 204, 10.1111/j.1572-0241.2000.01685.x

Siqueira, 2002, Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis, Gastrointest Endose, 56, 40, 10.1067/mge.2002.125105

Lindberg, 2002, Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis, Endoscopy, 34, 909, 10.1055/s-2002-35298

Mann, 2000, Elevated tumor marker CA 19-9: clinical interpretation and influence of obstructive jaundice, Eur J Surg Oncol, 26, 474, 10.1053/ejso.1999.0925

Levy, 2005, The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis, Dig Dis Sci, 50, 1734, 10.1007/s10620-005-2927-8

Nagrath, 2007, Isolation of rare circulating tumor cells in cancer patients by microchip technology, Nature, 450, 1235, 10.1038/nature06385

Ntouroupi, 2008, Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope, Br J Cancer, 99, 789, 10.1038/sj.bjc.6604545

Maeda, 1996, The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver, Mod Pathol, 9, 901

Takada, 1995, Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay, Br J Cancer, 71, 160, 10.1038/bjc.1995.33

Brechot, 1997, Diagnostic and prognostic value of CYFRA 21-1 compared with other tumor markers in patients with non-small cell lung cancer: a prospective study of 116 patients, Eur J Cancer, 33, 385, 10.1016/S0959-8049(96)00498-4

Andreadis, 2005, Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy, J Urol, 174, 1771, 10.1097/01.ju.0000176742.53556.25

Nakata, 2004, Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumor marker for detecting disease relapse and assessing treatment efficacy in breast cancer, Br J Cancer, 91, 873, 10.1038/sj.bjc.6602074

Nakata, 1996, Clinical significance of serum CYFRA 21-1 in gastric cancer, Br J Cancer, 73, 1529, 10.1038/bjc.1996.288

Pujol, 2004, CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients, Br J Cancer, 90, 2097, 10.1038/sj.bjc.6601851

Kashihara, 1998, Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level, J Gastroenterol, 33, 447, 10.1007/s005350050112

Uenishi, 2008, Serum cytokeratin 19 fragment (CYFRA 21-1) as a prognostic factor in intrahepatic cholangiocarcinoma, Ann Surg Oncol, 15, 583, 10.1245/s10434-007-9650-y

Chapman, 1980, Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology, Gut, 21, 870, 10.1136/gut.21.10.870

Moreno Luna, 2006, Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis, Liver Transpl, 12, S15, 10.1002/lt.20938

Tischendorf, 2006, Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis, Endoscopy, 38, 665, 10.1055/s-2006-925257

de Groen, 1999, Biliary tract cancers, N Engl J Med, 341, 1368, 10.1056/NEJM199910283411807

Jarnagin, 2001, Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma, Ann Surg, 234, 507, 10.1097/00000658-200110000-00010

Farley, 1995, “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention, Mayo Clin Proc, 70, 425, 10.4065/70.5.425

Ito, 2008, Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence, Ann Surg, 248, 273, 10.1097/SLA.0b013e31817f2bfd

Charatcharoenwitthaya, 2008, Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis, Hepatology, 48, 1106, 10.1002/hep.22441

Liu, 2008, Detection of circulating cancer cells in lung cancer patients with a panel of marker genes, Biochem Biophys Res Commun, 372, 756, 10.1016/j.bbrc.2008.05.101